Repligen Corporation Common Stock vs Sony Group Corp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Sony Group Corp trades at $24.5 (market cap $140.46B). The key difference: Sony Group Corp is far larger — about 12.6× Repligen Corporation Common Stock's market cap, and Sony Group Corp pays a 0.65% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sony Group Corp for 96 Days on average.
| RGEN | SONY | |
|---|---|---|
Market Cap | $11.14B | $140.46B |
Volume | 1,259,263 | 5,764,125 |
Sector | Health | Technology |
52-Week High | $194.57 | $30.26 |
52-Week Low | $102.87 | $19.32 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $11.02B | $138.37B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Sony trades at $24.36, up 0.41% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats, though Q1 2026 missed expectations. Revenue remains stable around $12.96T with improving operating cash flow of $2.32T. Analyst sentiment is strongly positive with 11 buy ratings and no sell recommendations, while recent news highlights Sony's content moat and AI litigation developments.
Sony presents a compelling investment case with solid fundamentals and strong analyst support, though negative net income margin and ROE raise concerns. The stock's valuation appears reasonable with P/E of 20.65 and EV/EBITDA of 8.05. Key risks include content competition and AI-related legal challenges, while opportunities lie in Sony's entertainment ecosystem and strategic expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →